ATLASSAB Biotherapeutics (SABS) earnings date: Nov 5, 2026
SAB Biotherapeutics (SABS) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 5, 2026, before the open. Analysts expect EPS of -$0.27.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on SABS
| Last price | $3.31 (-1.3%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.6% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 5 reports |
These figures come from the same calibrated model and valuation as the SAB Biotherapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
SAB Biotherapeutics reports on Nov 5, 2026. One email the day before, with ATLAS’s read on SAB Biotherapeutics. You can switch it off at any time.
Alert me before SABS reportsFree to start. Creating an account takes under a minute.
Notify me when SAB Biotherapeutics reports
Track SABS free Add SAB Biotherapeutics to a free ATLAS watchlist and see its next report date in one place.
SABS earnings at a glance
| Next report (confirmed) | Thu, Nov 5, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.27 |
| Last report | Aug 6, 2026 · In line |
| Beat rate (last 5 reports) | 3 of 5 (60%) |
| Average EPS surprise | +15.1% |
| Average move around a report | ±5.5% (last 5) |
| Sector | Healthcare · Biotechnology |
SAB Biotherapeutics earnings history: last 5 reports
SAB Biotherapeutics last reported on Aug 6, 2026: EPS of -$0.28 against an estimate of -$0.28 (0.0% surprise), in line with the estimate.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 6, 2026 | -$0.28 | -$0.28 | 0.0% | In line | +3.5% |
| Jun 3, 2026 | $0.87 | $0.91 | +4.6% | Beat | -0.3% |
| Mar 9, 2026 | -$0.17 | -$0.41 | -141.2% | Miss | +8.2% |
| Feb 17, 2026 | $3.94 | $4.07 | +3.3% | Beat | -2.9% |
| Nov 14, 2025 | -$0.46 | $0.50 | +208.7% | Beat | +12.9% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for SABS
See the fair value, the probability range and the earnings history of SAB Biotherapeutics on its ATLAS page.
SAB Biotherapeutics (SABS) stock analysisPlans from €3.99 a month.
SAB Biotherapeutics earnings: frequently asked questions
When does SAB Biotherapeutics (SABS) report earnings?
SAB Biotherapeutics is scheduled to report on Thursday, November 5, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for SABS?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.27 per share (USD). Estimates can change before the report.
How often does SABS beat earnings estimates?
Of its last 5 reports with a recorded result, SAB Biotherapeutics beat the EPS estimate 3 times; the average surprise was +15.1%. Past results do not predict the next one.
How much does SABS move around earnings?
Over its last 5 reports the stock moved an average of 5.5% (absolute, from the close before the report day to the close after it), and finished higher 3 of 5 times.
Did SAB Biotherapeutics beat earnings estimates last quarter?
SAB Biotherapeutics last reported on Aug 6, 2026: EPS of -$0.28 against an estimate of -$0.28 (0.0% surprise), in line with the estimate.
How much does SABS usually move in a day?
On a normal trading day the ATLAS model puts SABS’s one-day range at about ±4.6%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 5, 2026
Educational information, not investment advice. Disclaimer